ILB-2109 plus toripalimab for advanced solid cancers
Treatments studied
Part of Cancer, Ear, nose & throat, Hormones & metabolism, Lungs & breathing, Mouth & dental, Skin, Women’s health & pregnancy clinical trials.
This Phase 1/2 study tests a combination medicine (ILB-2109) plus an immune therapy (toripalimab) in people with advanced solid tumors when standard treatments haven’t worked or aren’t available. It aims to find out if the treatment can shrink tumors and is safe enough to keep studying.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (18 to 80 years old).
- You have advanced solid cancer (metastatic or progressing) confirmed by biopsy or body-fluid test, with no effective standard treatment option.
- Your overall condition score is ECOG 0–2 (you can do most daily activities).
- You have labs that meet key safety thresholds (blood counts, liver/kidney function, and heart rhythm/QT measurements).
- You can have a reliable tumor assessment (tumor visible on scans or certain tumor marker blood tests) and you’re expected to live at least 3 months.
- If you can become pregnant, you must have a negative pregnancy test and agree to effective birth control during the study and for 90 days after the last ILB-2109 dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of the immunotherapy drug toripalimab with chemotherapy for women with locally advanced cervical cancer that has not been treated yet. The goal is to see if this approach can shrink tumors before standard radiation therapy.
This Phase 2 study tests toripalimab (an immune therapy) combined with CAV/IE chemotherapy for certain advanced or non-surgically removable sarcomas. It may help shrink tumors and slow disease when standard treatments have failed or don’t exist.
This trial tests a new drug (ES102) combined with an immunotherapy (Toripalimab) for people with advanced non-small cell lung cancer that has stopped responding to standard treatments. It may help those whose tumors have high PD-L1 levels.
This trial tests a new combination of two drugs (LTC004 and toripalimab) for people with advanced solid tumors that have stopped responding to standard immunotherapy. It aims to see if this combination can help when immunotherapy alone no longer works.
This study tests a new drug, ILB-3101, for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and how well it works.
This trial tests a new combination of two drugs (AL8326 and Toripalimab) for people with advanced solid tumors that have stopped responding to standard treatments or have no other options. The goal is to see if the combination is safe and shrinks tumors.
Hear when a new Head and Neck Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.